Neogenomics (NEO) Cash & Equivalents (2010 - 2026)

Neogenomics has reported Cash & Equivalents for 17 years, with the latest figure at $146.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 57.79% year-over-year to $146.1 million; the trailing twelve-month figure through Mar 2026 stood at $146.1 million (down 57.79% YoY), and the FY2025 full-year result was $159.6 million, down 56.51% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $146.1 million, down from $159.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $367.0 million in Q4 2024, with the low at $146.1 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $277.6 million across 5 years, with a median of $289.1 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 30.13% — and 2026, when it plunged 57.79%.
• Neogenomics' Cash & Equivalents stood at $263.2 million in 2022, then soared by 30.13% to $342.5 million in 2023, then increased by 7.16% to $367.0 million in 2024, then tumbled by 56.51% to $159.6 million in 2025, then decreased by 8.44% to $146.1 million in 2026.
• The last three Cash & Equivalents figures came in at $146.1 million (Q1 2026), $159.6 million (Q4 2025), and $164.1 million (Q3 2025), per Business Quant data.